Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based biopharmaceutical company Epix Pharmaceuticals has announced that Bayer Schering Pharma will transfer the worldwide commercial rights for the novel blood pool magnetic resonance angiography agent, Vasovist, to Epix.
Subscribe to our email newsletter
The collaboration agreement between the two parties will terminate effective March 1, 2009; until that time, Bayer Schering Pharma will continue to provide continued supply of Vasovist in the 19 countries where it is currently marketed.
According to Bayer Schering Pharma, the company is committed to ensuring that patients and physicians in the countries where Vasovist is currently marketed have continued access to Vasovist during this transition period.
Vasovist is an injectable intravascular contrast agent designed to provide improved imaging of the vascular system through magnetic resonance angiography imaging (MRA).
Elkan Gamzu, interim CEO of Epix, said: “We are pleased to regain complete worldwide commercial rights for Vasovist which has a PDUFA date of December 31, 2008. Pending FDA approval, Vasovist is positioned to become the first MRA contrast agent approved in the US and it could be launched in 2009.
“Our goal remains to maximize the commercial value of Vasovist and we are committed to executing our monetization strategy which includes finding a marketing and commercialization partner for Vasovist.”